Clinical trials: Chemoradiotherapy
Pancreatic Cancer
Borderline Resectable Pancreatic Cancer: Gemcitabine/Docetaxel and Oxaliplatin Based Chemo/RT
This study is being conducted to find out what effects (good and bad) that a combination of treatment with chemotherapy, radiation therapy and surgery has on you and your pancreatic cancer.
- Trial name
- NCT00761241
- Testing
- Gemcitabine, Docetaxel, 5FU, Oxaliplatin, Alpha-interferon, Abdominal/pelvic radiation therapy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Benaroya Research Institute
Head and Neck Cancer
Fluorouracil, Cisplatin, and Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Nasopharyngeal Cancer
RATIONALE: Drugs used in chemotherapy, such as fluorouracil and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00093665
- Testing
- cisplatin, fluorouracil, radiation therapy
- Where
- 7 sites in Japan
- Volunteers
- 90 people
- Sponsor
- Aichi Cancer Center
Resectable Esophageal Cancer, GastroEsophageal Cancer
Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer
This is a 2 part Phase I/II clinical trial evaluating the safety, tolerability and efficacy of avelumab in combination with chemoradiation in patients with resectable esophageal and gastroesophageal cancer.
- Trial name
- NCT03490292
- Testing
- Avelumab combined with Chemoradiation, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Wisconsin, Madison
Non-small Cell Lung Cancer, Cardiac Toxicity
Evaluation of Impedance Cardiography for Assessing Hemodynamic Shifts in Patients With LA-NSCLC During Treatment.
This study aimed to investigate the role of impedance cardiography (ICG) in evaluating hemodynamic changes during the 6-minute walk test (6MWT) in patients with locally advanced non-small cell lung cancer (LA-NSCLC) who underwent…
- Trial name
- NCT06277388
- Testing
- Impedance cardiography
- Where
- China
- Volunteers
- 231 people
- Sponsor
- Sun Yat-sen University
Gastric Cancer, Surgery
Phase III Randomized Trial of Adjuvant XP Chemotherapy and XP/RT for Resected Gastric Adenocarcinoma
The objective of the trial is to compare disease-free survival between adjuvant capecitabine/cisplatin alone vs capecitabine/cisplatin with radiotherapy (chemoradiation) in curatively resected gastric cancer patients.
- Trial name
- NCT00323830
- Testing
- Capecitabine, cisplatin, Radiotherapy (+/-)
- Where
- South Korea
- Volunteers
- 458 people
- Sponsor
- Samsung Medical Center
Adenocarcinoma of the Pancreas, Stage IA Pancreatic Cancer
Perioperative Therapy for Resectable Pancreatic Cancer
This phase II trial studies how well giving combination chemotherapy together with intensity-modulated radiation therapy (IMRT) and surgery works in treating patients with localized pancreatic cancer that can be removed by…
- Conditions
- Adenocarcinoma of the Pancreas, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer
- Trial name
- NCT00609336
- Testing
- gemcitabine hydrochloride, docetaxel, capecitabine
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Washington
Lung Cancer
Cetuximab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Unresectable Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer
RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00081302
- Testing
- cetuximab, carboplatin, paclitaxel
- Where
- United States
- Sponsor
- Radiation Therapy Oncology Group
Head and Neck Squamous Cell Carcinoma
Pembrolizumab in HNSCC With Residual Disease After Radiation
This is a phase II study for patients with squamous cell carcinoma of the head and neck who have residual disease following definitive therapy with radiation (with or without systemic therapy).
- Trial name
- NCT02892201
- Testing
- Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Yale University
Irresectable Squamous Cell or Adenocarcinoma of the Oesophagus
Radio-chemotherapy With or Without Panitumumab (Vectibix®) in Irresectable Squamous Cell Carcinoma or Adenocarcinoma of the Oesophagus
For esophageal cancer that can not be removed by surgery, the choice of treatment is a combination of chemotherapy and radiotherapy. We call this combination- (or concurrent) chemoradiotherapy.
- Trial name
- PANORAMIC (NCT01262183)
- Testing
- CRT + Panitumumab, Concurrent chemoradiation therapy without panitumumab
- Where
- Netherlands
- Volunteers
- 4 people
- Sponsor
- Radboud University Medical Center
Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma
PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
The purpose of this study is to explore the efficacy and safety of compare the efficacy and safety of PD-1 inhibitor and chemotherapy（treatment group） with chemoradiotherapy（control group） in neoadjuvant treatment of resectable…
- Trial name
- REVO (NCT05007145)
- Testing
- PD-1 inhibitor, Albumin-Bound Paclitaxel, Cisplatin
- Where
- 6 sites in China
- Volunteers
- 92 people
- Sponsor
- Fujian Cancer Hospital
Anal Cancer, Anal Carcinoma
Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. A Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group
The RADIANCE multicenter, randomized phase II trial will assess the efficacy of durvalumab, a PD-L1 immune checkpoint inhibitor, in combination with primary mitomycin C (MMC)/5-fluorouracil (5-FU)-based radiochemotherapy (RCT) in…
- Conditions
- Anal Cancer, Anal Carcinoma, Anal Cancer Stage III, Anal Cancer Stage II
- Trial name
- RADIANCE (NCT04230759)
- Testing
- Chemotherapy, Radiation, Durvalumab
- Where
- 25 sites in Austria, Germany and 1 more
- Volunteers
- 180 people
- Sponsor
- Goethe University
Rectal Neoplasms, Adenocarcinoma
Preoperative Chemoradiation Followed by Chemotherapy for Locally Advanced Rectal Cancer
The current standard treatment of locally advanced rectal cancer (clinical stage II or III) is preoperative radiation with chemotherapy (CRT) followed by surgery.
- Trial name
- PREPARE (NCT01952951)
- Testing
- Capecitabine Oxaliplatin, pelvic radiation capecitabine 5-fluorouracil
- Where
- 7 sites in South Korea
- Volunteers
- 110 people
- Sponsor
- National Cancer Center, Korea
Diffuse Intrinsic Pontine Glioma
Nimotuzumab in Combined With Chemoradiotherapy to Treat the Newly Diagnosed Diffuse Intrinsic Pontine Glioma in Children
This is a prospective, open-label, single arm, multicenter clinical study. The purpose of the study is to evaluate the clinical efficacy and safety of combination Nimotuzumab with concurrent radiochemotherapy in children with…
- Trial name
- NCT04532229
- Testing
- Nimotuzumab+CRT(concurrent IMRT and TMZ)
- Where
- 8 sites in China
- Volunteers
- 48 people
- Sponsor
- Biotech Pharmaceutical Co., Ltd.
Esophageal Cancer
Chemoradiotherapy Versus Esophagectomy After Endoscopic Resection for Superficial Esophageal Squamous Cell Carcinoma
This is a randomized noninferiority multicenter trial. Patients will be stratified according to the participating hospital. Patients will be randomized to one of the treatment arms.
- Trial name
- ASSURE (NCT03306901)
- Testing
- Esophagectomy, 5-fluorouracil, Cisplatin
- Where
- 9 sites in South Korea
- Volunteers
- 240 people
- Sponsor
- Samsung Medical Center
Cervical Cancer
Efficacy and Safety Study of Concurrent Chemoradiation Therapy to Treat Locally Advanced Cervical Cancer
Concurrent chemoradiation therapy with weekly cisplatin is the current standard treatment for patients with locally advanced cervical cancer. However, weekly cisplatin is related to renal toxicity and not convenient regimen.
- Trial name
- NCT01461772
- Testing
- Radiation therapy, Carboplatin, Cisplatin
- Where
- South Korea
- Volunteers
- 21 people
- Sponsor
- Asan Medical Center
Rectal Cancer Recurrent
Surgery Plus Chemo Versus Chemoradiotherapy Followed by Surgery Plus Chemo for Locally Recurrent Rectal Cancer
JCOG1801 is a randomized phase III trial which was initiated in Japan in August 2019 to confirm the superiority of preoperative chemoradiotherapy followed by surgery plus adjuvant chemotherapy for local relapse-free survival over…
- Trial name
- JCOG1801 (NCT04288999)
- Testing
- Chemotherapy, Preoperative radiotherapy, Procedure
- Where
- 45 sites in Japan
- Volunteers
- 110 people
- Sponsor
- National Cancer Center Hospital East
Rectal Cancer
Preoperative Chemoradiation With Capecitabine and Cetuximab
feasibility and tolerance of preoperative therapy with Cetuximab in combination with Capecitabine and radiotherapy for patients with locally advanced operable rectal carcinoma collection of response rate (T-downstaging…
- Trial name
- NCT00297128
- Testing
- Capecitabine, Cetuximab
- Where
- 10 sites in Austria
- Volunteers
- 31 people
- Sponsor
- Austrian Breast & Colorectal Cancer Study Group
Rectal Cancer
"Watch and Wait" After Neo-adjuvant Chemoradiotherapy for Primary Locally Advanced Rectal Cancer.
Among patients treated for locally advanced rectal cancer with neo-adjuvant radio-chemotherapy, about 15% will have complete clinical response in terms of no visible tumor or ulcerations on the site of the primary tumor, or…
- Trial name
- NORWAIT (NCT03402477)
- Where
- 7 sites in Norway
- Volunteers
- 86 people
- Sponsor
- Helse Stavanger HF
Disease-free Survival Rate
Phase Ⅱ Trial of Camrelizumab in Patients Without Distant Metastasis Nasopharyngeal Carcinoma
To see the effect if a combination of neoadjuvant chemotherapy combined with Camrelizumab followed by chemoradiotherapy in treating patients without distant metastasis nasopharyngeal carcinoma
- Trial name
- NCT04782765
- Testing
- Camrelizumab+Chemotherapy+Chemoradiotherapy
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Rectal Cancer
Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer
This trial will enroll patients with locally advanced rectal cancer (resectable and non-resectable).The phase Ib dose escalation portion of trial is designed to determine the maximum tolerated dose (MTD) of CRLX101 when combined…
- Trial name
- NCT02010567
- Testing
- CRLX101, Capecitabine, Radiotherapy
- Where
- 6 sites in United States
- Volunteers
- 32 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.